Kodiak Sciences fails to meet mid-to-late-stage study goal of eye drug

[February 23, 2022]  (Reuters) - Kodiak Sciences Inc said on Wednesday its experimental eye drug did not meet the main goal of a mid-to-late-stage trial, failing to show it was not inferior compared to Regeneron Pharmaceuticals' Eylea.

Shares of Kodiak Sciences were down over 60% in premarket trade.

The drug was being tested in 559 patients with wet macular degeneration, a chronic eye disorder that causes blurred vision or blind spots. While the trial showed the experimental drug, codenamed KSI-301, was safe, it did not improve the vision of the patients as compared to Eylea.

(Reporting by Leroy Leo; Editing by Krishna Chandra Eluri)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.